The estimated Net Worth of Garo H Armen is at least 14.5 百万$ dollars as of 15 February 2024. Garo Armen owns over 500,000 units of Agenus Inc stock worth over 3,530,465$ and over the last 21 years he sold AGEN stock worth over 1,007,854$. In addition, he makes 9,937,040$ as Chairman of the Board、 Chief Executive Officer、 Co-Founder at Agenus Inc.
Sign up
Garo Armen AGEN stock SEC Form 4 insiders trading
Garo has made over 8 trades of the Agenus Inc stock since 2011, according to the Form 4 filled with the SEC. Most recently he bought 500,000 units of AGEN stock worth 325,000$ on 15 February 2024.
The largest trade he's ever made was buying 2,150,976 units of Agenus Inc stock on 16 August 2011 worth over 1,096,998$. On average, Garo trades about 16,156 units every 21 days since 2004. As of 15 February 2024 he still owns at least 625,969 units of Agenus Inc stock.
You can see the complete history of Garo Armen stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Garo Armen biography
Dr. Garo H. Armen Ph.D. serves as Chairman of the Board, Chief Executive Officer, Co-Founder of the Company. Dr. Armen is Chairman and Chief Executive Officer of Agenus Inc., which he co-founded in 1994. Dr. Armen brings to our Board a deep historical and practical knowledge of the business of the Company and its technologies, as well as years of expertise in the financial and biopharmaceutical arenas. From mid-2002 through 2004, he was Chairman of the Board of Directors for the biopharmaceutical company Elan Corporation, plc which he helped restructure. Dr. Armen currently serves as non-executive Chairman of the Board of Directors of Protagenic Therapeutics, Inc., a publicly held biotechnology company. Dr. Armen is also the founder and Chairman of the Children of Armenia Fund, a philanthropic organization established in 2000 that is dedicated to the positive development of the children and youth of rural Armenia. He holds a Ph.D. degree in physical organic chemistry from the City University of New York.
What is the salary of Garo Armen?
As the Chairman of the Board、 Chief Executive Officer、 Co-Founder of Agenus Inc, the total compensation of Garo Armen at Agenus Inc is 9,937,040$. There are no executives at Agenus Inc getting paid more.
How old is Garo Armen?
Garo Armen is 66, he's been the Chairman of the Board、 Chief Executive Officer、 Co-Founder of Agenus Inc since 1994. There are 3 older and 10 younger executives at Agenus Inc. The oldest executive at Agenus Inc is Wadih Jordan, 85, who is the Independent Director.
What's Garo Armen's mailing address?
Garo's mailing address filed with the SEC is C/O AGENUS INC., 3 FORBES ROAD, LEXINGTON, MA, 02421.
Insiders trading at Agenus Inc
Over the last 23 years, insiders at Agenus Inc have traded over 24,466,328$ worth of Agenus Inc stock and bought 13,248,226 units worth 63,837,873$ . The most active insiders traders include Associates Gp Llcqvt Fund V...、Noubar Afeyan、Corp Incyte. On average, Agenus Inc executives and independent directors trade stock every 99 days with the average trade being worth of 2,230,885$. The most recent stock trade was executed by Garo H Armen on 15 February 2024, trading 500,000 units of AGEN stock currently worth 325,000$.
What does Agenus Inc do?
agenus is an immunology company discovering and developing novel checkpoint modulators, vaccines and adjuvants to treat cancer and other diseases. we are a dedicated group of scientists, researchers, biotechnologists, physicians, and businesspeople working together toward one goal: to discover and develop therapies that can unleash the innate power of the body’s immune system to treat and potentially cure hard-to-treat cancers and other diseases. our product candidates are designed to work by educating and activating the body’s immune system for a precise and potent attack on cancer. our strategy is to help unlock the potential of one of the most exciting breakthrough areas in cancer treatment in decades, and to develop single agent and combination immune-oncology therapies that can help save lives. our approaches are driven by three platform technologies, including: • our antibody platforms, including our proprietary retrocyte display™ and secant® technologies, and our antibody
What does Agenus Inc's logo look like?
Complete history of Garo Armen stock trades at Agenus Inc
Agenus Inc executives and stock owners
Agenus Inc executives and other stock owners filed with the SEC include:
-
Garo Armen,
Chairman of the Board, Chief Executive Officer, Co-Founder -
Jennifer Buell,
President, Chief Operating Officer -
Evan Kearns,
Chief Compliance Officer, Vice President, General Counsel, Corporate Secretary -
Dr. Garo H. Armen,
Founder, Exec. Chairman & CEO -
Dr. Garo H. Armen Ph.D.,
Founder, Exec. Chairman & CEO -
Brian Corvese,
Independent Director -
Timothy Wright,
Lead Independent Director -
Ulf Wiinberg,
Independent Director -
Christine Klaskin,
Chief Accounting Officer, Vice President - Finance -
Wadih Jordan,
Independent Director -
Allison Jeynes-Ellis,
Independent Director -
Christine M. Klaskin,
VP of Fin., Principal Financial Officer & Principal Accounting Officer -
Susan Hirsch,
Director -
Paul Clark,
Director -
Donald Vidic,
Vice President - Head of Commercial -
Dr. Steven J. O'Day M.D., Ph.D.,
Chief Medical Officer -
Julie DeSander,
Chief Bus. Officer -
Dr. Marcus Antonius van Dijk Ph.D.,
Chief Technology Officer -
Alfred Dadson,
Chief Manufacturing Officer -
Dhan Chand,
Scientific Director & Head of Drug Discovery -
Paulo Moreira,
Global Head of Clinical Operations -
John Castle,
Head of Translational Medicine & Bioinformatics -
Adam Krauss J.D.,
Chief Legal & Compliance Officer -
Regina Grebla Ph.D.,
VP of Investor Relations & Communications -
Dr. Marc van Dijk Ph.D.,
Chief Technology Officer -
Shahzad Malik,
Director -
Jean Marie Cuillerot,
Chief Medical Officer -
Corp Incyte,
10% owner -
Charles Evan Ballantyne,
CFO -
Robert Benjamin Stein,
Chief Scientific Officer -
Shalini Sharp,
Director -
Alex Duncan,
Chief Technology Officer -
Eisen Margaret,
Director -
Ozer Baysal,
Chief Business Officer -
Associates Gp Llcqvt Fund V...,
-
Tom Dechaene,
Director -
Timothy G Rothwell,
Director -
John Hatsopoulos,
Director -
Hyam Levitsky,
Director -
Kerry Wentworth,
VP, Reg Affairs & Clinical Ops -
Karen Valentine,
Chief Legal Officer -
Alastair Jj Wood,
Director -
Pramod Srivastava,
Director -
Roman Chicz,
SVP Research & Preclinical Dev -
Bruce Leicher,
VP, General Counsel -
Russell Herndon,
Pres, Commercial Operations -
Gamil De Chadarevian,
Director -
Mark Kessel,
Director -
Peter J. Thornton,
CFO & Sr. VP -
Frank V Iii Atlee,
Director -
Noubar Afeyan,
Director -
Jeff D Clark,
Chief Financial Officer -
Renu Gupta,
Sr. Vice President -
Neal Gordon,
SrVP, Manufacturing Operations -
Christian Cortis,
Chief Strategy Officer -
Thomas L Harrison,
-
Adam Krauss,
Chief Legal Officer -
Steven J O'day,
Chief Medical Officer